The burden Of heart failure

Slides:



Advertisements
Similar presentations
Perioperative Management of Heart Failure Gamal Fouad S Zaki, MD Professor of Anesthesiology Ain Shams University
Advertisements

Ranexa™ for Chronic Angina An Unmet Need
UNMET NEED AHF/HF Disease Awareness. Morbidity and Mortality: Patients with heart failure are on a downward spiral, with frequent hospitalizations and.
Diastolic Heart Failure, HFpEF, HFnEF: What are we treating anyway? Charles M. Rasmussen, MD FACC.
Treatment-Resistant Hypertension: Magnitude of the Problem Power Over Pressure
PATHOPHYSIOLOGY HF/AHF Disease Awareness. HF=heart failure; LV=left ventricular 1. Alla et al. Heart Fail Rev 2007;12:91–5; 2. Gheorghiade et al. Am J.
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
McMurray JJV, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL et al on behalf of the CHARM investigators Relationship of dose of background angiotensin-converting.
Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial -- the Losartan Heart Failure Survival.
CHARM Program: 3 Component trials comparing candesartan with placebo.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
חזק בהגנה לבבית Valsartan in Heart Failure
Improving survival in symptomatic ischemic patients with left ventricular dysfunction Beneficial effects of long-term trimetazidine* therapy Fragasso G.
Journal Club Alcohol and Health: Current Evidence January–February 2007.
SOLVD (Studies of Left Ventricular Dysfunction)
Heart Failure Whistle Stop Talks No 1 HFrEF and HFpEF Definitions for Diagnosis Susie Bowell BA Hons, RGN Heart Failure Specialist Nurse.
Loop diuretics VS venous ultrafiltration in cardio-renal syndrome Radek Debiec SHO Renal Medicine LGH Sept 2013.
EPIDEMIOLOGY AND HISTORY AHF/HF Disease Awareness.
Heart Failure Whistle Stop Talks No. 2 Classification Implications Susie Bowell BA Hons, RGN Heart Failure Specialist Nurse.
Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Heart Failure Ben Starnes MD FACC Interventional Cardiology
ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Myocardial Ischemia Redefined: Optimal Care in CAD.
Current Management of Heart Failure GP clinical update 17 th June 2015 Dr Raj Bilku Consultant Cardiologist Clinical Lead Cardiology QEH.
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis Following Myocardial Infarction: The VALIANT Echo Study Anil Verma,
Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.
Update on Valsartan Špinar J.. System renin-angiotensin-aldosteron angiotensinogen angiotensin I angiotensin II aldosteron ANP,BNP thirst resorp. Na +
To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE DISEASE MANAGEMENT STANDARDS.
S. HUNT Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE MORTALITY STATISTICS.
New Technologies & Challenges in optimizing the “heart health” of Australia Professor Simon Stewart Head, Preventative Cardiology
Heart failure: The national burden AHA. Heart disease and stroke statistics–2005 update. Koelling TM et al. Am Heart J. 2004;147:74-8. VBWG Affects 1 million.
The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.
Review of an article Not all Angiotension-Converting Enzyme (ACE) inhibitors are Equal: Focus on Ramipril and Perindopril DiNicolantonio J, Lavie C, O’Keefe.
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE PATIENT QUALITY OF LIFE STATISTICS.
Heart failure and comorbidities
Contemporary Management of Myocardial Ischemia
Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients with Heart Failure with preserved Ejection Fraction Effect of Spironolactone.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
  Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, M.D., M.P.H, M.B.A. On behalf.
DIAGNOSIS No symptoms = no heart failure. DIAGNOSIS No symptoms = no heart failure.
JOURNAL REVIEW HEART FAILURE MANAGEMENT – BETA BLOCKERS
Revascularization in Patients With Left Ventricular Dysfunction:
Clinical need for determination of vulnerable plaques
Heart Failure Management
CLINICAL DILEMMAS IN HEART FAILURE:
RAAS Blockade: Focus on ACEI
Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.
European Heart Association Journal 2007 April
Nat. Rev. Cardiol. doi: /nrcardio
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:
Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care  Marc Cohen, MD  Mayo Clinic Proceedings 
Presentation transcript:

The burden Of heart failure © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0027a

Heart Failure is a complex syndrome involving multiple organ systems and is associated with a high mortality and morbidity burden Heart failure (HF) is a chronic condition, punctuated by acute episodes Each acute event results in further organ damage: myocardial and renal damage occurring during such episodes may contribute to progressive left ventricular and/or renal dysfunction Increasing frequency of acute events with disease progression leads to higher rates of hospitalization and increased risk of mortality Chronic decline Cardiac function and quality of life Hospitalisations for acute decompensation episodes Disease progression Adapted from Gheorghiade et al. Am J Cardiol 2005;96:11–17; Gheorghiade and Pang. J Am Coll Cardiol 2009;53:557–73

Heart failure is a major and growing public health problem Prevalence1 Incidence2–4 new cases per 100,000 per year Growth5 2% 219 HF Prevalence of the population in Europe have HF1 130 70‡ Increasing prevalence of risk factors5,6 Aging population5 Improved post-MI survival5 As many as 1 in 5 people aged 70–80 years have HF1 MI=myocardial infarction; ‡Calculated using the incidence rate of HF in 1997 for the population in Hong Kong and applying it to the Chinese population 1. Dickstein et al. Eur Heart J 2008;29:2388–442; 2. Go et al. Circulation 2013;127:e6–e245; 3. Allender et al. Coronary Heart Disease Statistics 2008; 4. Hung et al. Hong Kong Med J 2000;6:159–62; 5. Hunt et al. J Am Coll Cardiol 2009;53:e1–90; 6. Kearney et al. Lancet 2005; 365:217–23

Morbidity and mortality in Heart failure HF is associated with significant mortality 30 days 1 year 5 years Hospital post-diagnosis 4-7% in-hospital mortality rate‡1–3 ~10% mortality after 30 days†4 ~20% mortality after 1 year‡5 Up to 50% mortality after 5 years§6-8 HF=heart failure ‡Data from European patients hospitalized for heart failure in the European Society of Cardiology Heart Failure (ESC-HF) Pilot study and EuroHeart Failure Survey (EHFS) II †Analysis of HF data from 1,282 incident cases of HF in the Atherosclerosis Risk in Communities (ARIC) population-based study of n=15,792 individuals from four communities in the USA (1987–2002) §Reported rates vary but some publications include rates up to 50%68 1.Maggioni et al. Eur J Heart Fail 2010;12:1076–84; 2. Nieminen et al. Eur Heart J 2006;27:2725–36; 3. Cleland et al. Eur Heart J 2003;24:442–636; 4. Loehr et al. Am J Cardiol 2008;101:1016–22; 5. Maggioni et al. Eur J Heart Fail 2013;15:808–17; 6. Roger et al. JAMA 2004;292:344–50; 7. Levy et al. N Engl J Med 2002;347:1397–402; 8. Askoxylakis et al. BMC Cancer 2010;10:105

Morbidity and mortality in Heart failure HF with reduced EF and HF with preserved EF are associated with high levels of morbidity and mortality HF with reduced EF and HF with preserved EF are associated with high levels of mortality1 The prognosis for patients with chronic HF and preserved EF is substantially worse than that for patients with other conditions that increase CV risk‡2 40 HFrEF 30 Mortality (%) 20 HFpEF No therapies are proven to reduce morbidity and mortality in chronic HF with preserved EF3 10 1 2 3 Years ‡Based on data comparing mortality and HF hospitalization rates from clinical trials in patients with HFpEF (n=3 trials) with similar data from clinical trials in patients of without HF but who were of a similar age, comorbidity profile and had other conditions that increase CV risk (stable angina pectoris [n=1 trial], diabetes [n=1 trial] or hypertension [n=5 trials]) CV=cardiovascular; EF=ejection fraction; HF=heart failure; HFpEF=heart failure with preserved ejection fraction; HFrEF=heart failure with reduced ejection fraction; LVEF=left ventricular ejection fraction 1.Meta-Analysis Global Group In Chronic heart failure (MAGGIC). Eur Heart J 2012;33:1750–7; 2. Campbell et al. J Am Coll Cardiol 2012;60:2349–56; 3. McMurray et al. Eur Heart J 2012;33:1787–847

Heart failure has a significant impact on quality of life Quality of life among patients with HF compared with the general population and other chronic conditions* General population General population aged 65-74 CARE-HF (Chronic heart failure) Type II diabetes Moderate motor neurone disease Parkinson's disease Non-small cell lung cancer 0.0 0.2 0.4 0.6 0.8 1.0 EQ-5Dindex score *Data from patients receiving optimal medical therapy with chronic heart failure due to left ventricular systolic dysfunction and dysynchrony enrolled in the CARE-HF trial EQ-5D™ is a standardized instrument for use as a measure of health outcome, providing a simple descriptive profile and a single index value for health status Reprinted from the European Journal of Heart Failure, 7(2), Calvert MJ, et al. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study, 243–51, Published on behalf of the European Society of Cardiology. All rights reserved, Copyright (2005) the authors, with permission of John Wiley & Sons, Inc. CARE-HF=CArdiac REsynchronisation in Heart Failure; HF=heart failure Calvert et al. Eur J Heart Fail 2005;7:243–51

Heart failure imposes a significant economic burden on the healthcare system 70% of the cost of HF is due to hospitalizations1 ~2% of the total healthcare budget in many countries is spent on the treatment of HF1 ~10% of the cost of HF is due to pharmacological treatment2 Due to an ageing population, the total cost of HF in the USA alone is expected to increase ~127% 2030 by ‡3 ‡USA estimate includes direct costs (total annual medical spending) and indirect costs (lost productivity due to morbidity and mortality) 1. Dickstein et al. Eur Heart J 2008;29:2388–442; 2. Hunt et al. J Am Coll Cardiol 2009;53:e1–90; 3. Heidenreich et al. Circulation 2013 [epub ahead of print]

Unmet therapeutic need in acute Heart failure: Many patients are discharged with unresolved congestion, which is associated with poor long-term outcomes Persistent congestion after hospitalization for HF predicts poor survival‡2 Number of signs of congestion after discharge from hospital‡ 2-year mortality rate 24% 13% 1–2 33% of patients hospitalized for HF in Europe have signs of congestion at discharge1 3–5 59% ‡Patients with New York Heart Association class IV heart failure (HF; n=146) were re-assessed for signs of congestion 4–6 weeks after discharge. Criteria for congestion were orthopnea, raised jugular venous pressure, the need to increase the dose of diuretic during the past week, attending staff assessment of weight, and peripheral edema 1. Maggioni et al. Eur J Heart Fail 2010;12:1076–84; 2. Lucas et al. Am Heart J 2000;140:840–7

Unmet therapeutic need in chronic Heart failure HFrEF mortality remains high despite the introduction of new therapies that improve survival HFrEF survival rates have improved over time with the introduction of new therapies ACEI* ARB* β-blocker* MRA* 16% 17% Reduction in relative risk of mortality vs placebo 4.5% ARR; mean follow up of 41.4 months SOLVD1 3.0% ARR; median follow-up of 33.7 months CHARM-Alternative2 30% 34% 11.0% ARR; mean follow up of 24 months RALES4 5.5% ARR; mean follow up of 1.3 years CIBIS-II3 However, significant mortality remains5 *On top of standard therapy at the time of study (except in CHARM-Alternative where background ACEI therapy was excluded). Patient populations varied between trials and as such relative risk reductions cannot be directly compared. SOLVD (Studies of Left Ventricular Dysfunction), CIBIS-II (Cardiac Insufficiency Bisoprolol Study II) and RALES (Randomized Aldactone Evaluation Study) enrolled chronic HF patients with LVEF≤35%. CHARM-Alternative (Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity) enrolled chronic HF patients with LVEF≤40%. ARR=absolute risk reduction; HF=heart failure; MRA=mineralocorticoid receptor antagonist; RRR=relative risk reduction 1. SOLVD Investigators. N Engl J Med 1991;325:293–302; 2. Granger et al. Lancet 2003;362:772–6; 3. CIBIS-II Investigators. Lancet 1999;353:9–13; 4. Pitt et al. N Engl J Med 1999;341:709-17; 5. Roger et al. JAMA 2004;292:344–50

Summary Heart failure (HF) is a chronic condition, punctuated by acute episodes, which may affect multiple organ systems HF is associated with high morbidity and mortality and place a significant economic burden on healthcare systems Unresolved congestion at discharge is associated with poor long- term outcomes No therapies are proven to reduce morbidity and mortality in chronic HF with preserved EF The evidence base supporting long-term benefits of current treatments for acute HF is limited Early treatment with a therapy that targets the underlying pathophysiology of acute HF may improve long-term outcomes There is a need for therapeutic advances in HF